SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-24-000523
Filing Date
2024-01-12
Accepted
2024-01-12 16:30:21
Documents
14
Period of Report
2024-01-09
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tenx_8k.htm   iXBRL 8-K 29247
  Complete submission text file 0001654954-24-000523.txt   154545

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tenx-20240109.xsd EX-101.SCH 5720
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tenx-20240109_lab.xml EX-101.LAB 14667
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tenx-20240109_cal.xml EX-101.CAL 898
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tenx-20240109_pre.xml EX-101.PRE 9275
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tenx-20240109_def.xml EX-101.DEF 2099
8 EXTRACTED XBRL INSTANCE DOCUMENT tenx_8k_htm.xml XML 3611
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

IRS No.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34600 | Film No.: 24532396
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)